Following the American National Lung Screening Trial results in 2011 a consortium of
French experts met to edit a statement. Recent results of other randomized trials gave the …

An estimated 10–25% of lung cancers worldwide occur in never smokers, ie individuals
having smoked less than 100 cigarettes in their lifetime. Lung cancer in never smokers (LCINS) …

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

Purpose: Tumor somatic mutation analysis is part of the standard management of metastatic
lung cancer. However, physicians often have to deal with small biopsies and consequently …

In Europe, lung cancer ranks third among the most common cancers, remaining the biggest
killer. Since the publication of the first European Society of Radiology and European …

Introduction BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations are identified
in approximately 2% of non-small cell lung cancer (NSCLC). Because of the rarity of those …

Plasma circulating cell-free (cf)DNA is of interest in oncology because it has been shown to
contain tumour DNA and may thus be used as liquid biopsy. In nonsmall cell lung cancer (…

Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes in lifetime) is considered
as a distinct entity and harbours an original molecular profile. However, the epidemiological …

Background Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report
results from the French KBP-2020 real-life cohort. Methods KBP-2020 was a prospective …

BACKGROUND Specimens collected by CT scan-guided transthoracic core-needle biopsy (TTNB)
are frequently used for the diagnosis of lung nodules, but the clinical value of …